Boehringer Ingelheim exits Hikma Pharmaceuticals

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
ABBs-Block Trades

Boehringer Ingelheim exits Hikma Pharmaceuticals

Aidan Gregory
June 23, 2020 12:00 pm
Hikma_Pharma_PA_575_375
A logo sign outside of a facility occupied by Hikma Pharmaceuticals in Eatontown, New Jersey on April 11, 2020. (Photo by Kristoffer Tripplaar/Sipa USA) | Kris Tripplaar/SIPA USA/PA Images

German pharmaceuticals company Boehringer Ingelheim has sold its remaining stake in UK drug maker Hikma Pharmaceuticals, after a surge in investor interest in pharma stocks during the Covid-19 global pandemic.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

JP MorganHealth and BiotechEquityABBs-Block TradesUKEuropeEMEASRI
AG
Aidan Gregory
Gift this article